Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS
Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinas DF, Lou JS
Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases · 78 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Medical University of South Carolina
- Gobierno
- National Center for Research Resources
- Gobierno
- NIH Clinical Center
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NCCIH NIH HHS
- Subvenciones
- National Center for Complementary and Integrative Health (R01-AT00967-01); National Center for Complementary and Integrative Health (R01AT000967)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2008-01-01 · Amyotroph Lateral Scler · vol. 9 · número 5 · págs. 266–272
- Editorial
- Taylor & Francis
- Citado
- 107 citas · más que el 91% de estudios similares · 2.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 24 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Amyotrophic Lateral Sclerosis Research · Muscle Physiology and Disorders · Muscle metabolism and nutrition
- Palabras clave
- creatine monohydrate, disease progression, muscle strength, fatigue, respiratory function, forced vital capacity, ALSFRS, survival, quality of life, isometric voluntary contraction
- MeSH
- humans, amyotrophic lateral sclerosis, disease progression, creatine, placebos, vital capacity, treatment outcome, survival rate, double-blind method, muscle fatigue, quality of life, aged, middle aged, female, male, muscle strength, biomarkers
10 autores
- Jeffrey Rosenfeld🇺🇸Carolinas Medical Center
- Ruth M. King🇺🇸Carolinas Medical Center
- Carlayne E. Jackson🇺🇸The University of Texas at San Antonio Health Science Center
- Richard Bedlack🇺🇸 · autor de correspondenciaDuke University
- Richard J. Barohn🇺🇸University of Kansas
- Arthur R. Dick🇺🇸University of Kansas
- Lawrence H. Phillips🇺🇸University of Virginia
- John C. Chapin🇺🇸University of New Mexico
- Deborah F. Gelinas🇺🇸California Pacific Medical Center
- Jau-Shin Lou🇺🇸University of Oregon
Resumen
El texto original del estudio, en el idioma en que se publicó.
Our objective was to determine the effect of creatine monohydrate on disease progression in patients with amyotrophic lateral sclerosis (ALS). One hundred and seven patients with the diagnosis of probable or definite ALS, of less than five years duration from symptom onset, were randomized to either treatment with daily creatine monohydrate (5 g/d) or placebo. In this multicenter, double-blinded study we followed changes in disease progression: using quantitative measures of strength via maximal isometric voluntary contraction, forced vital capacity, ALSFRS, quality of life, fatigue and survival. Patients were followed for nine months. The results showed that creatine monohydrate did not significantly improve motor, respiratory or functional capacity in this patient population. The drug was well tolerated and the study groups well balanced, especially considering the absence of forced vital capacity criteria for entrance into the study. There was a trend toward improved survival in patients taking daily creatine monohydrate and this was identical to the trend seen in another recently published report of creatine in ALS patients 1. In conclusion, creatine monohydrate (5 g/d) did not have an obvious benefit on the multiple markers of disease progression measured over nine months. We measured fatigue during isometric contraction and found no significant improvement despite anecdotal patient reports prior to and during the study. The trend toward improved survival was also found in another recently completed blinded trial using creatine monohydrate. Further investigation on the possible survival benefit of creatine in this patient population is ongoing.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.